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CLINICAL INVESTIGATIONS 
Infarct vessel status after intravenous tissue 
plasminogen activator and acute coronary 
angioplasty: Prediction of clinical outcome 
To determine the risk of arterial reocclusion or recurrent ischemia after acute intervention in 
myocardial infarction, we analyzed the results of coronary arteriography performed acutely and 
at 1 week in 50 consecutive patients who received acute intervention. Successful recanaliration 
of the infarct vessel was achieved in 46 (92%) patients after therapy with intravenous tissue 
plasminogen activator, percutaneous coronary angioplasty, or both. Follow-up angiography in 44 
showed early reocclusion in 10 patients (23%). Intermittent patency during acute arteriography 
was always associated with reocclusion; suboptimal (Thrombolysis in Myocardial Infarction [TIMI] 
class 2) flow was associated with a 50% rate of reocclusion. Although residual stenosis of >50% 
alone was not predictive of rethrombosis, 90% of all reocclusions were associated with either 
stenosis >50%, TIMI 2 flow, or intermittent patency. Absence of these angiographic risk factors 
predicted a 95% patency rate at follow-up. In-hospital cardiac complications occurred in 17 of 23 
(74%) patients with residual stenosis of >50% (death in four, ischemia in 13), and late 
revascularization was required in 53% of survivors. Only 15% of the group with <50% stenosis 
had an in-hospital ischemic event (p < 0.001). Thus, after acute intervention, an infarct vessel 
with intermittent patency or suboptimal flow is associated with a high rate of reocclusion. 
Residual stenosis 250% appears to predict a high incidence of negative in-hospital clinical 
outcomes and the need for subsequent revascularization. (AM HEART J 1988;115:1.) 
Cindy L. Grines, M.D., Eric J. Topol, M.D., Eric R. Bates, M.D., Jack E. Juni, M.D., 
Joseph A. Walton, Jr., M.D., and William W. O’Neill, M.D. Ann Arbor, Mich. 
Recently, results of several large randomized trials 
have shown a reduction in mortality in acute myo- 
cardial infarction (MI) with the early use of throm- 
bolytic agents.‘-* Despite the reduction in mortality 
observed with thrombolytic therapy, the incidence 
of reinfarction or recurrent ischemic events is 
increased.1*2,5 Acute angiographic studies have 
shown that after successful thrombolysis, there is a 
high-grade residual coronary stenosis in most 
patients.6 Emergent percutaneous transluminal cor- 
onary angioplasty (PTCA) has the potential to 
reduce infarct vessel stenosis and may prevent 
recurrent ischemia.7r8 
With the likelihood of wide-scale use of intrave- 
nous thrombolysis, it will become increasingly 
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important to select those patients who need early 
definitive revascularization. The present study was 
undertaken to define whether there are arterio- 
graphic predictors of adverse clinical outcome and 
early reocclusion of infarct vessel. 
METHODS 
Study design. The study design has been described 
previously.g Briefly, 50 consecutive patients with acute 
MI, who were initially seen within 6 hours of onset of 
symptoms were randomly assigned on a 3:l basis to groups 
receiving either intravenous recombinant tissue plasmino- 
gen activator (t-PA), 1.25 mg/kg over 3 hours, or place- 
bo. 
Coronary angiography was performed at 60,90, and 120 
minutes after the infusion was started. The final infarct 
vessel patency determination was made at 120 minutes 
according to the Thrombolysis in Myocardial Infarction 
(TIMI) study classificationlo. Infarct vessels showing 
TIM1 2 or 3 flow patterns were considered to be patent. If 
residual stenosis X0% was present in a patent vessel, 
these patients were randomly assigned to either emergent 
PTCA or no PTCA. Patients with significant disease of 
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Fig. 1. Relationship between residual stenosis of infarct-related artery and subsequent in-hospital 
cardiac complications. 
the left main artery were excluded from randomization. 
Those patients with an occluded artery defined as TIMI 0 
or 1 underwent emergency angioplasty to attempt reperfu- 
sion. 
All patients received 5000 units of heparin at the time of 
arterial access and an additional 5000 units just before 
coronary angioplasty if this procedure was performed 
during acute catheterization. After patients left the cath- 
eterization laboratory, they were given a continuous infu- 
sion of heparin 1000 unit&r, which was maintained until 
follow-up catheterization except for a few hours on the 
second hospital day when the arterial access sheath was 
removed. Patients were also treated with aspirin (325 
mg/day), dipyridamole (75 mg three times/day), and 
diltiazem (30 to 60 mg four times/day). 
Repeat cardiac catheterization was performed on day 7. 
Reocclusion of an infarct vessel was defined as a vessel 
that was patent (TIM1 2 or 3 flow) at the completion of 
acute intervention that was found to have TIM1 0 or 1 flow 
at follow-up angiography. 
Angiographic analysis. Coronary arteriograms ob- 
tained during acute intervention were subsequently ana- 
lyzed to visually assess the presence of thrombus and 
arterial dissection. Intraluminal thrombus was defined as 
a circular intraluminal filling defect or persistent contrast 
staining. Intimal dissection was diagnosed if a linear 
filling defect was present at the dilatation site. Intermit- 
tent coronary patency was defined as adequate (TIM1 2 to 
3) flow that was spontaneously reduced to TIM1 0 to 1 on 
a later angiogram. Qualitative and quantitative coronary 
arteriographic analysis was performed by one observer 
blinded to patient identity, therapy, and effects of thera- 
PY- 
Infarct vessel stenosis was determined by quantitative 
angiography with the use of an automated edge-detection 
computer algorith.ll To determine the percentage of the 
diameter of the stenosis, end-diastolic frames were chosen 
from the coronary arteriogram that demonstrated the 
most severe stenosis. These were digitized into 256 x 256 
eight-bit matrices by means of a tine film projector 
equipped with a primary beam splitter coupled to a 
fixed-gain video camera and a video-to-digital converter. 
Images were stored in the memory of a digital radiograph- 
ic computer (DPS 41OOC, ADAC Laboratories, San Jose, 
Calif.) for subsequent processing. All values reported are 
quantitative angiographic results except when it was not 
possible to use the results of software analysis because of 
vessel overlap or inadequate film quality for digitization 
The latter occurred in nine of the patients in the study 
and in these, the percentage of the diameter of the stenosis 
was determined by calipers. 
Submaximal exercise testing with thallium-201 
tomographic imaging. A submaximal stress test with 
thallium-201 tomographic imaging was performed before 
discharge (3 to 10 days after infarction). The patients’ 
cardiac medications were not discontinued for the study. 
Upright treadmill exercise was performed in 3-minute 
uninterrupted stages with a constant speed of 2 miles/hr 
and a 3% grade increment for each stage. Complete 
12-lead ECGs were obtained at rest and at the end of each 
stage of exercise. Thallium-201 chloride (3 mCi) was 
injected intravenously at peak exercise and exercise was 
continued for one additional minute. Tomographic gam- 
ma camera imaging was then performed immediately with 
delayed views obtained 3 hours later. Exercise was termi- 
nated when one of the following conditions occurred: a 
target heart rate of 130 bpm, angina, marked ST segment 
depression, hypotension, serious ventricular arrhythmia, 
or exhaustion. The ECG was interpreted as positive for 
ischemia when the patient developed 2 mm or more of 
horizontal ST segment depression compared to the base- 
line tracing. 
Scintigraphic imaging was performed by means of a 
wide-field-of-view gamma camera (GE 400AT) equipped 
with a general-purpose, parallel-hole collimator. Image 
data were acquired in 64 projections over a 180-degree arc 
beginning with the right anterior oblique and ending with 
the left posterior oblique position. Images were obtained 
in a 64 X 64 word mode image with 30,000 to 50,000 
counts/image. Total acquisition time was approximately 
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Table I. Baseline demographic and angiographic data* Table II. Clinical and angiographic outcomes 
Stenosis Stenosis 
Variables >50% (n = 23) <50% (n = 27) >50% (n=23) ~50% (n =27J P 
No. of patients 
Age 
Male/female 
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Time to reperfusion = Time from onset of chest pain to angiographically 
documented patency of infarct vessel; LAD = left anterior descending 
artery; CX = circumflex artery; RCA = right coronary artery. 
*There were no significant @ < 0.05) differences between groups for the 
variables listed. 
20 minutes. Tomographic reconstruction was then per- 
formed by means of a commercial convolution/back projec- 
tion algorithm (GE STAR, General Electric, Milwaukee, 
Wise.) without attenuation correction. The reconstructed 
image data were reformatted to produce vertical, horizontal 
long-axis, and short-axis planes of section. Comparable 
images were obtained at the 3-hour imaging session. 
An image defect was considered present if there was a 
discrete region of absent or decreased activity estimated 
visually. The defect was anatomically localized as apical, 
anterior, septal, inferior, or lateral with t.he use of all 
sections. A defect present immediately after exercise and 
again at 3 hours’ delay was considered to be indicative of 
infarction, whereas a defect present only immediately 
after exercise was considered to reflect isdhemia. Either 
partial or complete resolution of a defect was considered 
evidence of reversible ischemia. If the reversible defect 
occurred adjacent to the zone of infarction, it was consid- 
ered to represent periinfarct ischemia; if it occurred at a 
site removed from the zone of infarction, it was considered 
to represent distant ischemia. 
Statistical evaluation. Data are presented as mean +- 1 
standard deviation unless otherwise stipulated. Student’s 
t and Fisher exact tests were used for statistical analysis 
where appropriate. Differences were considered signifi- 
cant at the p < 0.05 level. 
Clinical outcomes. Patients were monitored through- 
out their hospitalization for the following clinical events: 
(1) death; (2) postinfarction angina-recurrent chest pain 
at rest with accompanying ECG changes i.n the infarct 
territory; (3) reinfarction-prolonged chest discomfort 
with attendant enzymatic confirmation of creatine 
kinase-MB elevation; (4) exercise-induced ischemia-sub- 
maximal exercise testing before discharge demonstrating 







Need for delayed 
PTCAICABG 
4 0 0.001 
8 4 -co.05 
3 1 NS 
7 0 <O.OOl 
17 4 <O.OOl 
10 1 <O.OOl 
CABG = Coronary artery bypass graft; NS = not significant. 
zone. Reversible defects in the noninfarct zones were 
excluded. Subjects who required additional revasculariza- 
tion procedures before exercise testing were also excluded. 
Clinical events were coded by investigators who were 
blinded to the results of coronary angiographic analysis. 
Patients were considered to have reached a clinical end 
point if there was a recurrence of ischemia, at which time 
such patients were considered for revascularization with 
coronary angioplasty or coronary artery bypass surgery. 
RESULTS 
Angiographic results. Demographic and clinical 
data for the 50 patients have been previously report- 
ed.g The results of infarct vessel patency are as 
follows: two of the 12 patients who received placebo 
(17 % ) showed infarct vessel patency. Eleven of 
these patients underwent PTCA, which was success- 
ful in nine. Of the 38 patients receiving t-PA, 71% 
had a patent infarct vessel at 90 minutes and by 120 
minutes, 32 of 38 patients (84 % ) had a patent vessel. 
It is noteworthy that five of these patients showed 
intermittent patency and occlusion during serial 
angiography. At six patients with failed t-PA throm- 
bolysis underwent PTCA, flow was successfully rees- 
tablised in four. Of the 32 patients with successful 
t-PA thrombolysis, one underwent emergency 
bypass surgery because of left main coronary artery 
disease and three had 60% residual stenosis of the 
infarct vessel.. Of the 28 patients with high-grade 
stenoses after thrombolysis, 13 were randomly 
assigned to no PTCA and 15 were randomly 
assigned to immediate PTCA. All angioplasties in 
this group were successful with the mean stenosis 
decreasing from 80.8 + 8.2% to 32.5 ? 15%. With 
the addition of PTCA in patients with occluded 
vessels, overall patency was increased to 92 % . 
Hospital course. Cardiac complications including 
death or spontaneous or provocable ischemia 
occurred in 21 patients. Fig. 1 shows the spectrum of 
severity of infarct vessel residual stenosis after acute 
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Fig. 2. Incidence of individual adverse cardiac events during hospitalization in two groups: ~50% and 
<50% residual stenosis. 
intervention and its relationship to recurrent is- 
chemic events. Of the 20 patients who had a cardiac 
complication, 17 (85 % ) had infarct vessel residual 
stenosis ~50 % ; but 24 of 30 (80 % ) of those with an 
uncomplicated hospital course had insignificant ste- 
nosis (p < 0.001). This predominance of adverse 
clinical events in patients with X0% stenosis 
prompted a more detailed analysis of the angio- 
graphic subgroups. 
High-grade residual stenosis, defined as more 
than 50% diameter narrowing, was present in 23 
patients. This group comprised four patients with 
unsuccessful recanalization, four who underwent 
PTCA that was initially thought to be successful but 
who were later found to have 250% stenosis by 
quantitative arteriography, and 15 who did not 
undergo PTCA. Of the 27 patients with residual 
stenosis of less than 50%) 25 underwent PTCA to 
reduce the stenosis; the remaining two patients had 
insignificant stenosis remaining after thrombolysis 
alone. There were no statistical differences in sex, 
age, time to reperfusion, location of infarct vessel, or 
presence of multivessel disease between the two 
groups (Table I). 
Table II describes the incidence of in-hospital 
death or ischemia in the two groups: ~50% or 
<50% residual stenosis. There were four deaths in 
the trial. All four deaths occurred in patients with 
high-grade residual stenosis 0, < 0.001); three of 
these patients had undergone unsuccessful reperfu- 
sion. The infarct-related artery was the right coro- 
nary in two and left anterior descending in two. Two 
of these patients had received placebo, recanaliza- 
tion did not occur spontaneously, and angioplasty 
was unsuccessful in achieving sustained patency. 
One patient failed t-PA thrombolysis and had only 
brief reperfusion after PTCA before the artery 
reoccluded in the laboratory. The other death was in 
a 73-year-old man who received t-PA (5.2 hours 
after the onset of chest pain) and emergent angio- 
plasty (at 7.5 hours) but had a very extensive 
anterior infarction. Although PTCA was initially 
thought to be successful, subsequent analysis 
showed 55% residual stenosis with TIM1 2 flow, 
thrombus, and arterial dissection. All four patients 
developed cardiogenic shock and recurrent ventricu- 
lar tachycardia and fibrillation before death. 
In addition to death, other adverse in-hospital 
clinical events were associated with high-grade 
residual stenosis (Fig. I). Three of 19 (16%) survi- 
vors with residual stenosis >50% had in-hospital 
reinfarction but only 1 of 27 survivors (4%) with 
minor residual obstruction (p = 0.15). Postinfarc- 
tion angina occurred in 8 of the 19 (42%) survivors 
with high-grade stenosis compared to only four 
(15%) patients with <SO% residual stenosis 
(p < 0.05). Of the 14 patients with high-grade resid- 
ual stenosis of the infarct artery who underwent 
exercise tomographic thallium scintigraphy, seven 
(50%) showed evidence of periinfarct ischemia. 
Only one patient had ECG changes diagnostic of 
ischemia, the remaining ECGs could not be inter- 
preted because of changes at baseline. Of the 23 
patients with minor residual stenosis who under- 
went exercise testing, none had provocable ischemia 
(p < 0.001). 
Cardiac complications, including postinfarction 
angina, recurrent infarction, exercise-induced ische- 
mia, or death, were observed in 74 % of patients with 
residual stenosis >50% vs 15% of the group with 
<50% stenosis (p < 0.001). 
The need for delayed revascularization of the 
infarct artery was also determined for the two 
groups (Fig. 2). Fifty-three percent of survivors with 
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Fig. 3. Cumulative patient events including death, reinfarction, and spontaneous or provocable ischemia 
for two groups: ~50% and <50%. Late revascularization with bypass surgery or PTCA was performed for 
recurrent ischemia in 53% of survivors with ~50% stenosis. 
residual stenosis of the infarct artery 2’50% under- 
went late revascularization with either angioplasty 
or bypass surgery. Each patient received the addi- 
tional intervention for spontaneous or exercise- 
induced ischemia as previously defined. This 53% 
incidence of late revascularization for patients with 
high-grade residual lesions compares to only 4% in 
the group with <50% stenosis (p < 0.001). 
Reocclusion. Of the 46 patients with successful 
recanalization, 44 had follow-up coronary arteriog- 
raphy. In 10 patients the infarct artery was reoc- 
eluded at follow-up, which represents an incidence 
of 23%. 
Several angiographic features of the infarct artery 
at the completion of the acute intervention were 
evaluated to determine the relationship to early 
reocclusion. Time to reperfusion, location of infarct 
vessel, presence of thrombus or dissection, use of 
t-PA or placebo, use of PTCA, and successful vs 
unsuccessful t-PA thrombolysis were all considered 
and found not to be significantly different between 
patent and reoccluded groups. High-grade residual 
stenosis of the infarct artery was present in 50% of 
the vessels that reoccluded but not significantly 
different from those who remained patent (41%). 
Only 26% of vessels with residual stenosis of >50% 
were reoccluded at follow-up. TIM1 2 (suboptimal) 
flow was present in 30% of those v8essels that 
reoccluded, and its presence was associated with a 
50% reocclusion rate compared to a rate of only 
18% in those vessels with TIM1 3 flow (p = 0.09). 
Intermittent patency was present in onl,y five arte- 
ries and was associated with unsuccessful reperfu- 
sion in two. The three arteries with successful 
recanalization but intermittent patency during the 
acute procedure all were found to be reoccluded at 
follow-up catheterization (Fig. 3). 
It is noteworthy that 90% of all reocclusions were 
associated with at least one of three angiographic 
features of infarct artery: high-grade residual steno- 
sis, TIM1 2 flow, or intermittent patency during 
acute intervention. Absence of these risk factors 
predicted a 95% patency rate at follow-up. 
In five patients, reocclusion was associated with 
chest pain and ECG changes. In three of these five 
patients, symptomatic reocclusion occurred within 
24 hours after initial therapy. Reocclusion was silent 
in the remaining five patients. It should be noted 
that four of these five patients with silent reocclu- 
sion had well-developed collateral arteries to the 
infarct-related artery and one demonstrated periin- 
farct ischemia by exercise thallium. 
DISCUSSION 
Recurrent ischemia. Our results confirm the high 
incidence of reocclusion and recurrent ischemia 
after reperfusion therapy for acute MI. Use of 
intravenous t-PA, PTCA, or both may achieve high 
infarct vessel patency rates (92 % ). Despite this high 
initial patency rate, a significant number of these 
patients (17 of 50) had recurrent ischemia or died 
during hospitalization. Eighty-five percent of 
patients with an in-hospital cardiac event had resid- 
ual stenosis of the infarct artery ~50%. These 
patients had either not undergone PTCA or bad a 
suboptimal result of angioplasty. 
6 Grines et al. 
Post-infarction angina occurred spontaneously in 
42 % of survivors with high-grade stenosis. Exercise- 
induced periinfarct ischemia by thallium scintigra- 
phy was present in 50% of those with infarct vessel 
stenosis > 50 % . 
The high incidence of exercise-induced ischemia 
in this study may be related to enhanced myocardial 
salvage or greater sensitivity.of tomographic thalli- 
um scintigraphy. Only one of seven patients with 
periinfarct ischemia by thallium developed ischemic 
ECG changes with exercise. It is known that stress 
ECG is not a sensitive measure of ischemia in the 
setting of baseline ST segment changes or Q waves.12 
The sensitivity of thallium imaging after infarction 
is greater than stress ECG alone and a positive 
result has been shown to have poor prognostic 
implications.13 
All deaths occurred in patients with high-grade 
residual stenosis; three of these four patients had 
unsuccessful reperfusion. Other investigators have 
also found a higher mortality rate in patients with 
an occluded infarct vesse1.14-16 Although the numbers 
are small, the lack of mortality among patients with 
a widely patent infarct vessel after t-PA and angio- 
plasty is noteworthy. 
Spontaneous or provocable ischemia prompted 
delayed in-hospital revascularization with PTCA or 
bypass grafting in 53 % of survivors with high-grade 
infarct vessel stenosis. This finding underscores the 
importance of a high-grade lesion of the infarct 
vessel for instability. 
Predictors of reocclusion. Coronary arterial reoc- 
elusion remains a significant problem after success- 
ful thrombolytic therapy. Recent studies have 
shown that after successful thrombolysis by means 
of 90- to 180-minute infusions of t-PA, early reocclu- 
sion occurs in 33 % to 45 % of infarct arteries.“, l8 
With prolonged (6- to g-hour) infusions of t-PA in a 
larger trial of 386 patients, the combined incidence 
of reocclusion and recurrent ischemic events was less 
than 20% .I9 In the present study, the relatively high 
incidence of reocclusion and recurrent ischemic 
events probably relates to the lower total dose of 
t-PA and the shorter duration of infusion used. 
Suboptimal (TIM1 2) flow was associated with a 
higher rate of reocclusion, which may have resulted 
from the increased likelihood of rethrombosis in a 
diminished flow state. An interesting finding was 
that of intermittent patency of the infarct artery 
observed between the 60-, 90-, and 120-minute 
angiograms. This finding was observed in five arte- 
ries, two which failed reperfusion despite t-PA and 
PTCA, and the remaining three vessels reoccluded. 
Therefore, intermittent patency during infusion of 
t-PA resulted in a totally occluded infarct artery in 
each instance. Fluctuations in coronary flow after 
experimental thrombosis and reflow have been pre- 
viously documented. 2o This finding may represent 
platelet-mediated vasoconstriction or enhanced 
thrombotic tendency. 
One half of all reocclusions were associated with 
chest pain and ECG changes prompting emergency 
recatheterization. Four of five “silent” reocclusions 
occurred in patients with well-developed collateral 
arteries completely filling the infarct artery at the 
time of follow-up catheterization. One of these 
patients showed periinfarct redistribution on exer- 
cise thallium scintigraphy. This data would suggest 
that “silent” reocclusions are not always the result 
of lack of viable myocardium perfused by the infarct 
vessel. The development of collateral arteries may 
have protected these patients from reinfarction or 
perhaps denervation of the infarct area prevents 
clinically recognized angina. Silent ischemia may, in 
fact, be more common after acute MI.21*22 
Limitations. The results are from a relatively small 
population of patients who underwent acute inter- 
vention; thus, they must be interpreted with cau- 
tion. A patient with total occlusion of the infarct 
artery may have a particularly poor prognosis com- 
pared to a patient with partial reperfusion.23 Thus, 
inclusion of patients with total (100 % ) occlusion in 
the group with ~50% residual stenosis in our study 
may represent a particularly skewed group with 
respect to negative clinical outcome. However, only 
4 of 50 patients bad unsuccessful reperfusion. Three 
of the four deaths occurred in patients with 100% 
occlusion. The remaining patient with unsuccessfu 
reperfusion had no in-hospital cardiac complica- 
tions. 
The need for delayed revascularization was deter- 
mined by recurrent ischemic events. However, 
despite documented ischemia in three patients with 
<50 % residual stenosis, revascularization was only 
performed in one. In many cases the requirement for 
delayed PTCA or bypass surgery may have been the 
presence of high-grade stenosis. 
implications. These data identify patientsat high 
risk for reocclusion of the infarct artery after t-PA 
infusion, PTCA, or both. Patients with suboptimal 
(TIM1 2) flow or intermittent patency during infu- 
sion of t-PA had the highest rate of reocclusion. The 
inability to achieve sustained arterial patency 
despite the use of t-PA and PTCA suggests that 
other measures, including coronary bypass surgery, 
nonselective thrombolytic agents, or coronary 
stems, need to be evaluated in patients at high risk 
of reocclusion. After therapy with t-PA or angioplas- 
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ty, a vessel with residual stenosis of ~50% is 
associated with an increased risk of death, recurrent 
ischemic events, and the need for subsequent revas- 
cularization. This suggests that PTCA, if performed, 
should ideally reduce the stenosis of the infarct 
artery to <50%. 
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